RxDoctor Payments Data

Charles Abavare, DO

Adult Medicine · Tupelo, MSNPI 1790081156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.

$454in general payments, 2019–2025

Across 26 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$100
  • Novo Nordisk$87
  • Teva Pharmaceuticals USA, Inc.$71
  • Amgen$41
  • Genentech USA, Inc.$33
  • Boston Scientific$28
  • plus $94 from 7 others

What the payments were for

  • Food & beverage$454100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adult medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$83,713
Medicare patients
391
Services billed
4,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav150$943
Cefdinir36$644
Albuterol Sulfate HfaAlbuterol Sulfate24$544
Oseltamivir Phosphate23$506
Doxycycline Hyclate53$405
CefuroximeCefuroxime Axetil24$355
Mupirocin44$265
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$255
Azithromycin90$224
Prednisone119$192
Tizanidine Hcl53$174
Fluticasone Propionate25$159
Ondansetron OdtOndansetron18$138
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$128
Ciprofloxacin Hcl16$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$14$032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other adult medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →